Children's Hospital Westmead, Sydney, New South Wales, Australia.
Vaccine. 2010 Dec 10;29(1):45-50. doi: 10.1016/j.vaccine.2010.10.025. Epub 2010 Oct 23.
Reduced-antigen-content diphtheria-tetanus-acellular-pertussis (dTpa) vaccines are predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™, GlaxoSmithKline Biologicals) administration in 164 adults previously vaccinated with dTpa 10 years previously was evaluated. Before the decennial booster, 89.4% and 94.8% subjects were seroprotected (antibodies ≥0.1 IU/mL) for diphtheria and tetanus, respectively. One-month post-booster, all subjects were seroprotected/seropositive against all vaccine antigens. Robust GMC increases indicated a booster response similar to the first booster. The decennial booster was well tolerated without serious adverse events, consistent with product experience. This study supports replacing traditional Td boosters with dTpa, and use of Boostrix™ as a decennial booster. This study is registered at www.clinicaltrials.com NCT00548171.
低抗原含量白喉-破伤风-无细胞百日咳（dTpa）疫苗主要推荐终生使用一次。对 164 名在 10 年前接种过 dTpa 的成年人进行了第二次 dTpa（BoostrixTM，葛兰素史克生物制品公司）接种评估。在十年一次的加强针之前，分别有 89.4%和 94.8%的受试者对破伤风和白喉具有血清保护作用（抗体≥0.1 IU/mL）。加强针接种一个月后，所有受试者对所有疫苗抗原均具有血清保护/阳性。强大的 GMC 增加表明加强针反应与第一次加强针相似。十年一次的加强针耐受性良好，没有严重不良事件，与产品经验一致。这项研究支持用 dTpa 替代传统的 Td 加强针，并使用 BoostrixTM 作为十年一次的加强针。这项研究在 www.clinicaltrials.com 上注册，编号为 NCT00548171。
